Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling

Cancer Letters

Volumn 370, Issue 2, 2016, Pages 286-295

  Martins Neves, Sara R ^a,b,c   Paiva Oliveira, Daniela I ^a,b   Wijers Koster, Pauline M ^d   Abrunhosa, Antero J ^b,d   Fontes Ribeiro, Carlos ^a   Bovée, Judith V M G ^c   Cleton Jansen, Anne Marie ^c   Gomes, Célia M F ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Aldehyde dehydrogenase; Osteosarcoma; Pluripotency; Stemness; Wnt catenin

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BETA CATENIN; CISPLATIN; DOXORUBICIN; IWR 1; METHOTREXATE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ALDEHYDE DEHYDROGENASE; CTNNB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TREATMENT FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MNNG HOS CELL; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; OSTEOSARCOMA CELL LINE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BONE NEOPLASMS; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ALDEHYDE DEHYDROGENASE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; MICE; NEOPLASM PROTEINS; OSTEOSARCOMA; P-GLYCOPROTEINS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84949485364     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.013     Document Type: Article

References (46)

1. Pakos E.E., Nearchou A.D., Grimer R.J., Koumoullis H.D., Abudu A., Bramer J.A., et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur. J. Cancer 2009, 45:2367-2375. http://dx.doi.org/10.1016/j.ejca.2009.03.005.
2. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58. http://dx.doi.org/10.1038/nrc706.
3. Gomes C.M.F., van Paassen H., Romeo S., Welling M.M., Feitsma R.I.J., Abrunhosa A.J., et al. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. Nucl. Med. Biol 2006, 33:831-840. http://dx.doi.org/10.1016/j.nucmedbio.2006.07.011.
4. Oliver T.G., Mercer K.L., Sayles L.C., Burke J.R., Mendus D., Lovejoy K.S., et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010, 24:837-852. http://dx.doi.org/10.1101/gad.1897010.
5. Piskareva O., Harvey H., Nolan J., Conlon R., Alcock L., Buckley P., et al. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Lett 2015, 364:142-155. http://dx.doi.org/10.1016/j.canlet.2015.05.004.
6. Haslehurst A., Koti M., Dharsee M., Nuin P., Evans K., Geraci J., et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012, 12:91. http://dx.doi.org/10.1186/1471-2407-12-91.
7. Martins-Neves S.R., Lopes A., do Carmo A., Paiva A., Simoes P., Abrunhosa A., et al. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 2012, 12:139. http://dx.doi.org/10.1186/1471-2407-12-139.
8. Martins-Neves S.R., Corver W.E., Paiva-Oliveira D.I., van den Akker B.E.W.M., Briaire-de-Bruijn I.H., Bovée J.V.M.G., et al. Osteosarcoma stem cells have active Wnt/β-Catenin and overexpress SOX2 and KLF4. J. Cell. Physiol 2015, 10.1002/jcp.25179.
9. Friedmann-Morvinski D., Verma I.M. Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep 2014, 15:244-253. http://dx.doi.org/10.1002/embr.201338254.
10. Pisco A.O., Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'what does not kill me strengthens me'. Br. J. Cancer 2015, 112:1725-1732. http://dx.doi.org/10.1038/bjc.2015.146.
11. Hu X., Ghisolfi L., Keates A.C., Zhang J., Xiang S., Lee D.K., et al. Induction of cancer cell stemness by chemotherapy. Cell Cycle 2012, 11:2691-2698. http://dx.doi.org/10.4161/cc.21021.
12. Abubaker K., Latifi A., Luwor R., Nazaretian S., Zhu H., Quinn M., et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol. Cancer 2013, 12:24. http://dx.doi.org/10.1186/1476-4598-12-24.
13. Auffinger B., Tobias A.L., Han Y., Lee G., Guo D., Dey M., et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ 2014, 21:1119-1131. http://dx.doi.org/10.1038/cdd.2014.31.
14. Lagadec C., Vlashi E., Alhiyari Y., Phillips T.M., Bochkur Dratver M., Pajonk F. Radiation-induced notch signaling in breast cancer stem cells. Int J Radiat Oncol 2013, 87:609-618. http://dx.doi.org/10.1016/j.ijrobp.2013.06.2064.
15. Tang Q.L., Liang Y., Xie X.B., Yin J.Q., Zou C.Y., Zhao Z.Q., et al. Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer 2011, 30:426-432. http://dx.doi.org/10.5732/cjc.011.10127.
16. Ottaviano L., Schaefer K.L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010, 49:40-51. http://dx.doi.org/10.1002/gcc.20717.
17. van Kuppeveld F.J., van der Logt J.T., Angulo A.F., van Zoest M.J., Quint W.G., Niesters H.G., et al. Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl. Environ. Microbiol 1992, 58:2606-2615.
18. Shi Z., Tiwari A.K., Shukla S., Robey R.W., Singh S., Kim I.W., et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011, 71:3029-3041. http://dx.doi.org/10.1158/0008-5472.CAN-10-3820.
19. Ferreira-Teixeira M., Parada B., Rodrigues-Santos P., Alves V., Ramalho J., Caramelo F., et al. Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. Oncotarget 2015, in press.
20. Scionti I., Michelacci F., Pasello M., Hattinger C.M., Alberghini M., Manara M.C., et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann. Oncol 2008, 19:1500-1508. http://dx.doi.org/10.1093/annonc/mdn148.
21. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet 2012, 13:227-232. http://dx.doi.org/10.1038/nrg3185.
22. Jho E.H., Zhang T., Domon C., Joo C.K., Freund J.N., Costantini F. Wnt/β-Catenin/Tcf Signaling induces the transcription of axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol 2002, 22:1172-1183. http://dx.doi.org/10.1128/MCB.22.4.1172-1183.2002.
23. br mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer 2012, 12:549. http://dx.doi.org/10.1186/1471-2407-12-549.
24. bright populations in prostate cancer. Clin. Cancer Res 2013, 19:5361-5371. http://dx.doi.org/10.1158/1078-0432.CCR-12-2857.
25. Landen C.N., Goodman B., Katre A.A., Steg A.D., Nick A.M., Stone R.L., et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther 2010, 9:3186-3199. http://dx.doi.org/10.1158/1535-7163.MCT-10-0563.
26. Moreb J.S., Ucar D., Han S., Amory J.K., Goldstein A.S., Ostmark B., et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem. Biol. Interact 2012, 195:52-60. http://dx.doi.org/10.1016/j.cbi.2011.10.007.
27. van den Hoogen C., van der Horst G., Cheung H., Buijs J., Pelger R., van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin. Exp. Metastasis 2011, 28:615-625. http://dx.doi.org/10.1007/s10585-011-9395-7.
28. Saw Y.T., Yang J., Ng S.K., Liu S., Singh S., Singh M., et al. Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer 2012, 12:329. http://dx.doi.org/10.1186/1471-2407-12-329.
29. Marcato P., Dean C.A., Pan D., Araslanova R., Gillis M., Joshi M., et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29:32-45. http://dx.doi.org/10.1002/stem.563.
30. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell stem cell 2007, 1:555-567. http://dx.doi.org/10.1016/j.stem.2007.08.014.
31. Lou H., Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007, 26:1357-1360. http://dx.doi.org/10.1038/sj.onc.1210200.
32. Gregers J., Green H., Christensen I.J., Dalhoff K., Schroeder H., Carlsen N., et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015, 15:372-379. http://dx.doi.org/10.1038/tpj.2014.81.
33. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526. http://dx.doi.org/10.1038/nature11287.
34. Atlasi Y., Looijenga L., Fodde R. Cancer stem cells, pluripotency, and cellular heterogeneity: a WNTer perspective. Curr. Top. Dev. Biol 2014, 107:373-404. http://dx.doi.org/10.1016/B978-0-12-416022-4.00013-5.
35. Tsuchida R., Das B., Yeger H., Koren G., Shibuya M., Thorner P.S., et al. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 2008, 27:3923-3934. http://dx.doi.org/10.1038/onc.2008.38.
36. Hughes T.A., Brady H.J.M. E2F1 up-regulates the expression of the tumour suppressor axin2 both by activation of transcription and by mRNA stabilisation. Biochem. Biophys. Res. Commun 2005, 329:1267-1274. http://dx.doi.org/10.1016/j.bbrc.2005.02.102.
37. Kielman M.F., Rindapaa M., Gaspar C., van Poppel N., Breukel C., van Leeuwen S., et al. Apc modulates embryonic stem-cell differentiation by controlling the dosage of β-catenin signaling. Nat. Genet 2002, 32:594-605. http://dx.doi.org/10.1038/ng1045.
38. Cheng Y., Cheung A.K.L., Ko J.M.Y., Phoon Y.P., Chiu P.M., Lo P.H.Y., et al. Physiological β-catenin signaling controls self-renewal networks and generation of stem-like cells from nasopharyngeal carcinoma. BMC Cell Biol 2013, 14:1-13. http://dx.doi.org/10.1186/1471-2121-14-44.
39. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med 2004, 10. http://dx.doi.org/10.1038/nm979.
40. ten Berge D., Kurek D., Blauwkamp T., Koole W., Maas A., Eroglu E., et al. Embryonic stem cells require Wnt proteins to prevent differentiation to epiblast stem cells. Nat. Cell Biol 2011, 13. http://dx.doi.org/10.1038/ncb2314.
41. Yamada T., Takaoka A.S., Naishiro Y., Hayashi R., Maruyama K., Maesawa C., et al. Transactivation of the multidrug resistance 1 gene by T-Cell Factor 4/β-Catenin complex in early colorectal carcinogenesis. Cancer Res 2000, 60:4761-4766.
42. Stein U., Fleuter C., Siegel F., Smith J., Kopacek A., Scudiero D.A., et al. Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells. Br. J. Cancer 2012, 106:1395-1405. http://dx.doi.org/10.1038/bjc.2012.81.
43. Corrêa S., Binato R., Du Rocher B., Castelo-Branco M., Pizzatti L., Abdelhay E. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 2012, 12:1-11. http://dx.doi.org/10.1186/1471-2407-12-303.
44. Kim Y., Kim K.H., Lee J., Lee Y.A., Kim M., Lee S.J., et al. Wnt activation is implicated in glioblastoma radioresistance. Lab. Invest 2012, 92:466-473. http://dx.doi.org/10.1038/labinvest.2011.161.
45. Xu J., Prosperi J.R., Choudhury N., Olopade O.I., Goss K.H. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE 2015, 10:e0117097. http://dx.doi.org/10.1371/journal.pone.0117097.
46. Chang Y.W., Su Y.J., Hsiao M., Wei K.C., Lin W.H., Liang C.L., et al. Diverse targets of β-catenin during the epithelial-mesenchymal transition define cancer stem cells and predict disease relapse. Cancer Res 2015, 75:3398-3410. http://dx.doi.org/10.1158/0008-5472.CAN-14-3265.